

## DAFTAR PUSTAKA

- Alberts, B., Johnson, A., Lewis, J., Morgan, D., Raff, M., Roberts, K., & Walter, P. (2015). *Molecular Biology of The Cell* (6th ed.). Garland Science.
- Arnold, W. D., Kassar, D., & Kissel, J. T. (2015). Spinal muscular atrophy: Diagnosis and management in a new therapeutic era. *Muscle and Nerve*, 51(2), 157–167. <https://doi.org/10.1002/mus.24497>
- Ar Rochmah, M. *et al.* (2017) ‘Gender effects on the clinical phenotype in Japanese patients with spinal muscular atrophy’, *Kobe Journal of Medical Sciences*, 63(2), pp. E41–E44.
- Aydin, S. (2015). A short history, principles, and types of ELISA, and our laboratory experience with peptide/protein analyses using ELISA. *Peptides*, 72, 4–15. <https://doi.org/10.1016/j.peptides.2015.04.012>
- Bowerman, M., Murray, L. M., Beauvais, A., Pinheiro, B., & Kothary, R. (2012). A critical SMN threshold in mice dictates onset of an intermediate spinal muscular atrophy phenotype associated with a distinct neuromuscular junction pathology. *Neuromuscular Disorders*, 22(3), 263–276. <https://doi.org/10.1016/j.nmd.2011.09.007>
- Burlet, P., Huber, C., Bertrand, S., Ludosky, M. A., Zwaenepoel, I., Clermont, O., Roume, J., Delezoide, A. L., Cartaud, J., Munnich, A., & Lefebvre, S. (1998). The distribution of SMN protein complex in human fetal tissues and its alteration in spinal muscular atrophy. *Human Molecular Genetics*, 7(12).
- Chen, T. H. (2020). New and developing therapies in spinal muscular atrophy: From genotype to phenotype to treatment and where do we stand? *International Journal of Molecular Sciences*, 21(9), 1–20. <https://doi.org/10.3390/ijms21093297>
- Coover, D. D., Le, T. T., McAndrew, P. E., Strasswimmer, J., Crawford, T. O., Mendell, J. R., Coulson, S. E., Androphy, E. J., Prior, T. W., & Burghes, A. H. M. (1997). *The survival motor neuron protein in spinal muscular atrophy* (Vol. 6, Issue 8). Oxford University Press.
- Crawford, T. O., Paushkin, S. V., Kobayashi, D. T., Forrest, S. J., Joyce, C. L., Finkel, R. S., Kaufmann, P., Swoboda, K. J., Tiziano, D., Lomastro, R., Li, R. H., Trachtenberg, F. L., Plasterer, T., Chen, K. S., Bell, M., Jacoby, D., McBurney, R., Chung, W., Simard, L., & Sahin, M. (2012). Evaluation of SMN protein, transcript, and copy number in the biomarkers for spinal muscular atrophy (BforSMA) clinical study. *PLoS ONE*, 7(4). <https://doi.org/10.1371/journal.pone.0033572>
- Dhillon, S. (2020). *Risdiplam : First Approval. August*.
- Dubowitz, V. (1999). *Very severe spinal muscular atrophy (SMA type 0): an expanding clinical phenotype*. 3(2), 49–51.
- Eshraghi, M., McFall, E., Gibeault, S., & Kothary, R. (2016). Effect of genetic background on the phenotype of the Smn2B<sup>-</sup> mouse model of spinal muscular atrophy. *Human Molecular Genetics*, 25(20), 4494–4506. <https://doi.org/10.1093/hmg/ddw278>
- Farrar, M. A., & Kiernan, M. C. (2015). The Genetics of Spinal Muscular Atrophy: Progress and Challenges. In *Neurotherapeutics* (Vol. 12, Issue 2,

- pp. 290–302). Springer New York LLC.  
<https://doi.org/10.1007/s13311-014-0314-x>
- Finkel, R. S., Chiriboga, C. A., Vajsaar, J., Day, J. W., Montes, J., De Vivo, D. C., Bishop, K. M., Yamashita, M., Rigo, F., Hung, G., Schneider, E., Norris, D. A., Xia, S., Bennett, C. F., & Bishop, K. M. (2016). Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study. *The Lancet*, 388(10063), 3017–3026. [https://doi.org/https://doi.org/10.1016/S0140-6736\(16\)31408-8](https://doi.org/https://doi.org/10.1016/S0140-6736(16)31408-8)
- Fuss, I. J., Kanof, M. E., Smith, P. D., & Zola, H. (2009). Isolation of whole mononuclear Cells from peripheral blood and cord blood. *Current Protocols in Immunology*, SUPPL. 85, 1–8. <https://doi.org/10.1002/0471142735.im0701s85>
- Ghosh, R., Gilda, J. E., & Gomes, A. V. (2014). The necessity of and strategies for improving confidence in the accuracy of western blots. *Expert Review of Proteomics*, 11(5), 549–560. <https://doi.org/10.1586/14789450.2014.939635>
- Groen, E. J. N., Perenthaler, E., Courtney, N. L., Jordan, C. Y., Shorrock, H. K., Van Der Hoorn, D., Huang, Y. T., Murray, L. M., Viero, G., & Gilligwater, T. H. (2018). Temporal and tissue-specific variability of SMN protein levels in mouse models of spinal muscular atrophy. *Human Molecular Genetics*, 27(16), 2851–2862. <https://doi.org/10.1093/hmg/ddy195>
- Harding, B. N., Kariya, S., Monani, U. R., Chung, W. K., Benton, M., Yum, S. W., Tennekoon, G., & Finkel, R. S. (2015). Spectrum of Neuropathophysiology in Spinal Muscular Atrophy Type I. *Journal of Neuropathology & Experimental Neurology*, 74(1), 15–24. <https://doi.org/10.1097/NEN.0000000000000144>
- Keinath, M. C., Prior, D. E., & Prior, T. W. (2021). Spinal Muscular Atrophy: Mutations, Testing, and Clinical Relevance. *Application of Clinical Genetics*, 14, 11–25. <https://doi.org/https://doi.org/10.2147/TACG.S239603>
- Kobayashi, D. T., Olson, R. J., Sly, L., Swanson, C. J., Chung, B., Naryshkin, N., Narasimhan, J., Bhattacharyya, A., Mullenix, M., & Chen, K. S. (2011). Utility of survival motor neuron ELISA for spinal muscular atrophy clinical and preclinical analyses. *PLoS ONE*, 6(8). <https://doi.org/10.1371/journal.pone.0024269>
- Kolb, S. J., Gubitz, A. K., Olszewski, R. F., Ottinger, E., Sumner, C. J., Fischbeck, K. H., & Dreyfuss, G. (2006). A novel cell immunoassay to measure survival of motor neurons protein in blood cells. *BMC Neurology*, 6. <https://doi.org/10.1186/1471-2377-6-6>
- Kolb, S. J., & Kissel, J. T. (2015). Spinal Muscular Atrophy. In *Neurologic Clinics* (Vol. 33, Issue 4, pp. 831–846). W.B. Saunders. <https://doi.org/10.1016/j.ncl.2015.07.004>
- Konstantinou, & N., G. (2017). Food Allergens: Methods and Protocols. *EUFI Review*, 1592, 1–299. <https://doi.org/10.1007/978-1-4939-6925-8>
- Lefebvre, S., Burlet, P., Liu, Q., Bertrand, S., Clermont, O., Munnich, A., Dreyfuss, G., & Melki, J. (1997). Correlation between severity and SMN protein level in spinal muscular atrophy. *Nature Genetics*, 16(3), 265–269. <https://doi.org/https://doi.org/10.1038/ng0797-265>

- Lefebvre, S., Reboullet, S., Clermont, O., Burlet, P., Viollet, L., Benichou, B., Cruaud, C., Millasseau, P., Zeviani, M., Denis Le Paslier, Il, Fr, J., Cohen, D., Weissenbach, J., Munnich, A., & Melki, J. (1995). Identification and Characterization of a Spinal Muscular Atrophy-Determining Gene. In *Cell* (Vol. 80).
- Lin, C. W., Kalb, S. J., & Yeh, W. S. (2015). Delay in Diagnosis of Spinal Muscular Atrophy: A Systematic Literature Review. *Pediatric Neurology*, 53(4), 293–300. <https://doi.org/10.1016/j.pediatrneurol.2015.06.002>
- Mahmood, T., & Yang, P. C. (2012). Western blot: Technique, theory, and trouble shooting. *North American Journal of Medical Sciences*, 4(9), 429–434. <https://doi.org/10.4103/1947-2714.100998>
- Mendell, J. R., Al-Zaidy, S., Shell, R., Arnold, W. D., Rodino-Klapac, L. R., Prior, T. W., Lowes, L., Alfano, L., Berry, K., Church, K., Kissel, J. T., Nagendran, S., L'Italien, J., Sproule, D. M., Wells, C., Cardenas, J. A., Heitzer, M. D., Kaspar, A., Corcoran, S., ... Kaspar, B. K. (2017). Single-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy. *New England Journal of Medicine*, 377(18), 1713–1722. <https://doi.org/10.1056/nejmoa1706198>
- Mutsaers, C. A., Wishart, T. M., Lamont, D. J., Riessland, M., Schreml, J., Comley, L. H., Murray, L. M., Parson, S. H., Lochmüller, H., Wirth, B., Talbot, K., & Gillingwater, T. H. (2011). Reversible molecular pathology of skeletal muscle in spinal muscular atrophy. *Human Molecular Genetics*, 20(22), 4334–4344. <https://doi.org/10.1093/hmg/ddr360>
- Niba, E. T. E., Nishio, H., Wijaya, Y. O. S., Lai, P. S., Tozawa, T., Chiyonobu, T., Yamadera, M., Okamoto, K., Awano, H., Takeshima, Y., Saito, T., & Shinohara, M. (2020). Clinical phenotypes of spinal muscular atrophy patients with hybrid SMN gene. *Brain and Development*, 43(2), 294–302. <https://doi.org/10.1016/j.braindev.2020.09.005>
- Nurputra, D. K., Lai, P. S., Harahap, N. I. F., Morikawa, S., Yamamoto, T., Nishimura, N., Kubo, Y., Takeuchi, A., Saito, T., Takeshima, Y., Tohyama, Y., Tay, S. K. H., Low, P. S., Saito, K., & Nishio, H. (2013). Spinal muscular atrophy: From gene discovery to clinical trials. In *Annals of Human Genetics* (Vol. 77, Issue 5, pp. 435–463). <https://doi.org/10.1111/ahg.12031>
- Omrani, O., Bonyadi, M., & Barzgar, M. (2009). Molecular analysis of the SMN and NAIP genes in Iranian spinal muscular atrophy patients: Original Article. *Pediatrics International*, 51(2), 193–196. <https://doi.org/10.1111/j.1442-200X.2008.02665.x>
- Pierzchlewicz, K., Kępa, I., Podogrodzki, J., & Kotulska, K. (2021). Spinal Muscular Atrophy: The Use of Functional Motor Scales in the Era of Disease-Modifying Treatment. *Child Neurology Open*, 8, 2329048X2110087. <https://doi.org/10.1177/2329048x211008725>
- Prior, T. W., & Nagan, N. (2016). Spinal muscular atrophy: Overview of molecular diagnostic approaches. *Current Protocols in Human Genetics*, 2016, 9.27.1-9.27.13. <https://doi.org/10.1002/0471142905.hg0927s88>
- Sari, D. M., Biben, V., Wiwaha, G., & Hilmanto, D. (2023). Association between spinal muscular atrophy type and delayed diagnosis and the risk of spinal

- deformity in Indonesian patients. *European Journal of Medical Research*, 28(1), 1–8. <https://doi.org/10.1186/s40001-023-01098-3>
- Shah, K., & Maghsoudlou, P. (2016). Enzyme-linked immunosorbent assay (ELISA): The basics. *British Journal of Hospital Medicine*, 77(7), C98–C101. <https://doi.org/10.12968/hmed.2016.77.7.C98>
- Schorling, D. C., Pechmann, A., & Kirschner, J. (2020). Advances in Treatment of Spinal Muscular Atrophy - New Phenotypes, New Challenges, New Implications for Care. In *Journal of Neuromuscular Diseases* (Vol. 7, Issue 1, pp. 1–13). IOS Press. <https://doi.org/10.3233/JND-190424>
- Wadman, R. I., Stam, M., Jansen, M. D., Van Weegen, Y. Der, Wijngaarde, C. A., Harschnitz, O., Sodaar, P., Braun, K. P. J., Dooijes, D., Lemmink, H. H., Van Den Berg, L. H., & Van Ludo Der Pol, W. (2016). A comparative study of SMN protein and mRNA in blood and fibroblasts in patients with spinal muscular atrophy and healthy controls. *PLoS ONE*, 11(11). <https://doi.org/10.1371/journal.pone.0167087>
- Wang, C. H., Finkel, R. S., Bertini, E. S., Schroth, M., Simonds, A., Wong, B., Aloysius, A., Morrison, L., Main, M., Crawford, T. O., & Trela, A. (2007). Consensus statement for standard of care in spinal muscular atrophy. *Journal of Child Neurology*, 22(8), 1027–1049. <https://doi.org/10.1177/0883073807305788>
- Zappa, G., LoMauro, A., Baranello, G., Cavallo, E., Corti, P., Mastella, C., & Costantino, M. A. (2021). Intellectual abilities, language comprehension, speech, and motor function in children with spinal muscular atrophy type 1. *Journal of Neurodevelopmental Disorders*, 13(1), 1–11. <https://doi.org/10.1186/s11689-021-09355-4>
- Zaworski, P., Von Herrmann, K. M., Taylor, S., Sunshine, S. S., McCarthy, K., Risher, N., Newcomb, T., Weetall, M., Prior, T. W., Swoboda, K. J., Chen, K. S., & Paushkin, S. (2016). SMN Protein can be reliably measured in whole blood with an electrochemiluminescence (ECL) Immunoassay: Implications for clinical trials. *PLoS ONE*, 11(3). <https://doi.org/10.1371/journal.pone.0150640>